drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive T-cell immunotherapy; biologic)
drug_description
Single intravenous infusion of haploidentical donor-derived CD3+ T cells (CD4+ and CD8+) enriched for cytomegalovirus- and adenovirus-specificity via antigen stimulation and IFN-γ capture; designed to restore antiviral immunity post-transplant by recognizing viral peptides and killing infected cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, haploidentical donor-derived virus-specific T cells (CD4+ and CD8+) enriched by antigen stimulation and IFN-γ capture are adoptively transferred to restore antiviral immunity. Their native TCRs recognize CMV and adenovirus peptides presented by HLA on infected cells, leading to activation, IFN-γ secretion, and cytotoxic killing via perforin/granzyme, thereby clearing infected cells without genetic engineering.
drug_name
Allogeneic virus-specific T cells (VSTs) targeting CMV and adenovirus
nct_id_drug_ref
NCT05664126